Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (14374)	2/6/1998 4:16:00 PM
From: Alper H.YUKSEL	Read Replies (4) \| Respond to of 32384

Henry, How's today's volume compare to previous high volumes ? Also was today's rally retail or big boys ? TIA I think that yesterday's announcements do not really contain anything new and means much more to the general market than to the LGND threadsters (to the majority, I mean). I also believe that the new coverage initiations (buy/strong buy) are closer than most think, now that LGND is demonstrating strong and consistent performance regarding its financial status as well as the advancing pipeline. Based on these, I believe that 1998 will be a great opportunity for getting on board, before the 'Great Leap Forward' begins. Alper

To: Henry Niman who wrote (14374)	2/6/1998 5:03:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 32384

Just received my current edition of WORTH magazine and more positive coverage on Ligand. Special feature section quotes Jim McCamant and his Medical Technology Stock Letter: "Ligand is now filing for FDA approval of its first product, a treatment for KS, and THREE MORE DRUGS WILL BE FILED FOR APPROVAL in the next two years. In all, Ligand has more than 30 products in development, some of which target multibillion-dollar markets. Ligand also has seven attractive partnerships; the latest is a $174 million blockbuster deal with Lilly for treating metabolic diseases. Add it all together and the company is well positioned to be one of the few profitable biotechs in 1999." McCamant recommends buying up to $16.00.